Stakeholder Forum 2010
Start Date 14/06/2010 End Date 15/06/2010The Innovative Medicines Initiative welcomed 270 high level industry representatives, regulators, policy makers, top level scientific experts, patient representatives and science leaders at its first Stakeholder Forum in Brussels.
The event featured interesting presentations and lively discussions about the ongoing IMI projects, the IMI research agenda, the 3rd Call (2010) research topics and the IMI intellectual property policy.
Presentations
Plenary Sessions - 14 June 2010
Welcome and introduction (386kb)
Michel Goldman, Executive Director IMI
Reshaping biopharmaceutical research in Europe (109kb)
Roch Doliveux, Chief Executive Officer UCB
Public-Private Partnerships in the Health sector: the EU perspective (361kb)
Philippe Cupers, DG Research, European Commission
How to accelerate approval of innovative drugs (791kb)
Bruno Flamion, European Medicines Agency EMA
Patients' expectations (1.5MB)
Nicola Bedlington, Director European Patients' Forum
Opportunities for research organisations (155kb)
Stavros Malas, Chair States Representatives Group
Achievements and challenges ahead (244kb)
Michel Goldman, Executive Director IMI
Plenary sessions - 15 June 2010
Lessons learnt (61kb)
Michel Goldman, Executive Director IMI
The 3rd Call for proposals (2010) (266kb)
Titta Rosvall-Puplett, Director Research Directors Group, EFPIA
(Updated version - 29 June 2010)
New ways of sharing knowledge (113kb)
Magali Poinot, Legal Manager IMI
Revision of the IMI scientific strategy: Towards a new Research Agenda (700kb)
Christian Noë, chair of the Scientific Committee
Workshops on ongoing IMI Projects - 15 June 2010
DRUG SAFETY
- eTOX (493kb)
Ferran Sanz, Fundació IMIM - SAFE-T (4MB)
Michael Merz, Novartis - PROTECT (534kb)
Xavier Kurz, European Medicines Agency - MARCAR (428kb)
Jonathan Moggs, Novartis
NEUROSCIENCES
- PHARMA-COG (937kb)
Alexandra Auffret, University of Marseille - NEWMEDS (353kb)
Tine Bryan Stensbøl, H. Lundbeck - EUROPAIN (164kb)
Märta Segerdahl, AstraZeneca
TRAINING
- Eu2P (2.1MB)
Deborah Szafir , F. Hoffmann- La Roche - EMTRAIN (1.9MB)
Mike Hardman, AstraZeneca - SAFESCIMET (300kb)
Theodor Guentert, F. Hoffmann - La Roche - PHARMATRAIN (211kb)
Fritz Buhler, University of Basel